| Literature DB >> 35408555 |
Guangbo Xie1, Lan Tang1, Yu Xie1, Liyuan Xie2.
Abstract
Hericium erinaceus, a culinary and medicinal mushroom, is widely consumed in Asian countries. Chemical investigation on the fruiting bodies of Hericium erinaceus led to the isolation of one new ergostane-type sterol fatty acid ester, erinarol K (1); and eleven known compounds: 5α,8α -epidioxyergosta-6,22-dien-3β-yl linoleate (2); ethyl linoleate (3); linoleic acid (4); hericene A (5); hericene D (6); hericene E (7); ergosta-4,6,8(14),22-tetraen-3-one (8); hericenone F (9); ergosterol (10); ergosterol peroxide (11); 3β,5α,6α,22E-ergosta-7,22-diene-3,5,6-triol 6-oleate (12). The chemical structures of the compounds were determined by 1D and 2D NMR (nuclear magnetic resonance) spectroscopy, mass spectra, etc. Anti-inflammatory effects of the isolated aromatic compounds (5-7, 9) were evaluated in terms of inhibition of pro-inflammatory mediator (TNF-α, IL-6 and NO) production in lipopolysaccharide (LPS)-stimulated murine RAW 264.7 macrophage cells. The results showed that compounds 5 and 9 exhibited moderate activity against TNF-α (IC50: 78.50 μM and 62.46 μM), IL-6 (IC50: 56.33 μM and 48.50 μM) and NO (IC50: 87.31 μM and 76.16 μM) secretion. These results supply new information about the secondary metabolites of Hericium erinaceus and their anti-inflammatory effects.Entities:
Keywords: Hericium erinaceus; anti-inflammatory activity; isolation and structural elucidation; secondary metabolites
Mesh:
Substances:
Year: 2022 PMID: 35408555 PMCID: PMC9000484 DOI: 10.3390/molecules27072157
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of compounds 1–12.
1H NMR (400 MHz) and 13C NMR (100 MHz) Spectroscopic Data for 1 in CDCl3.
| Position | δC | δH ( | Position | δC | δH ( |
|---|---|---|---|---|---|
| 1 | 32.2 | 1.55 (m); 1.70 (m) | 24 | 42.8 | 1.84 (m) |
| 2 | 26.9 | 1.49 (m); 1.89 (m) | 25 | 33.0 | 1.46 (m) |
| 3 | 70.4 | 5.14 (m) | 26 | 19.9 | 0.83 (d, |
| 4 | 35.7 | 1.71 (m); 1.96 (m) | 27 | 19.6 | 0.82 (d, |
| 5 | 74.9 | - | 28 | 17.6 | 0.91 (d, |
| 6 | 73.4 | 4.80 (d, | 1′/1″ | 173.3, 173.0 | - |
| 7 | 114.0 | 5.28 (m) | 2′/2″ | 34.6, 34.6 | 2.25 (t, |
| 8 | 145.6 | - | 3′/3″ | 24.9, 25.0 | 1.60 (m) |
| 9 | 43.2 | 2.02 (m) | 4′/4″ | 29.1–29.7 | 1.23–1.35 (m) |
| 10 | 37.3 | - | 5′/5″ | 29.1–29.7 | 1.23–1.35 (m) |
| 11 | 21.9 | 1.57 (m) | 6′/6″ | 29.1–29.7 | 1.23–1.35 (m) |
| 12 | 39.1 | 1.32 (m); 2.05 (m) | 7′/7″ | 29.1–29.7 | 1.23–1.35 (m) |
| 13 | 43.7 | - | 8′/8″ | 27.2, 27.2 | 2.03 (m) |
| 14 | 54.8 | 1.91 (m) | 9′/9″ | 127.8, 127.9 | 5.30–5.40 (m) |
| 15 | 22.8 | 1.39 (m); 1.42 (m) | 10′/10″ | 128.0, 128.0 | 5.30–5.40 (m) |
| 16 | 27.8 | 1.72 (m) | 11′/11″ | 25.6, 25.6 | 2.77 (t, |
| 17 | 55.9 | 1.27 (m) | 12′/12″ | 130.0, 130.0 | 5.30–5.40 (m) |
| 18 | 12.3 | 0.57 (s) | 13′/13″ | 130.2, 130.2, | 5.30–5.40 (m) |
| 19 | 18.2 | 1.06 (s) | 14′/14″ | 27.2, 27.2 | 2.03 (m) |
| 20 | 40.4 | 2.01 (m) | 15′/15″ | 29.1–29.7 | 1.23–1.35 (m) |
| 21 | 21.1 | 1.02 (d, | 16′/16″ | 31.5, 31.9 | 1.26 (m) |
| 22 | 135.3 | 5.19 (m) | 17′/17″ | 22.5. 22.7 | 1.29 (m) |
| 23 | 132.1 | 5.21 (m) | 18′/18″ | 14.0, 14.1 | 0.88 (m) |
Figure 21H-1H COSY and key HMBC correlations of 1. (COSY: correlation spectroscopy).
Figure 3NOESY correlations of 1.
Figure 4Effects of compounds 5–7 and 9 on TNF-α production in LPS-stimulated raw 264.7 cells. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared with LPS-stimulated group. Aspirin (positive control).
IC50 values a (μM) of compounds 5–7 and 9 as inhibitors of TNF-α, IL-6 and NO.
| Compounds | TNF-α | IL-6 | NO |
|---|---|---|---|
|
| 78.50 ± 3.72 | 56.33 ± 6.81 | 87.31 ± 8.77 |
|
| 298.50 ± 18.77 | - | - |
|
| 168.30 ± 9.69 | - | - |
|
| 62.46 ± 3.18 | 48.50 ± 6.54 | 76.16 ± 9.11 |
| Aspirin b | 27.08 ± 1.86 | 28.43 ± 4.46 | 51.82 ± 8.62 |
a Data are expressed as mean ± SD; n = 5 independent experiments. b Positive control.
Figure 5Effects of compounds 5 and 9 on IL-6 (A) and NO (B) production in LPS-stimulated raw 264.7 cells. ** p < 0.01, and *** p < 0.001 compared with LPS-stimulated group. Aspirin (positive control).